Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy. Issue 7 (3rd July 2021)

• Record Type: Journal Article
• Authors: Kubo, Terufumi; Hirohashi, Yoshihiko; Tsukahara, Tomohide; Kanaseki, Takayuki; Murata, Kenji; Hasegawa, Tadashi; Torigoe, Toshihiko
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 7(2021)
• Page Start: 1940
• Page End: 1942
• Publication Date: 2021-07-03
• Subjects: Epithelioid granuloma -- Pd-L1 -- PD-1 -- tuberculosis; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2020.1870364
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The immune system is often called a double-edged sword, due to the inextricable link between cancer immunity and allergy/autoimmunity. Intriguingly, a growing number of cases have been reported in which PD-1 blockade triggers the exacerbation of tuberculosis (TB), an organ-invasive granulomatous disease caused by bacterial infection. As a result, the exacerbation of TB is now considered a severe adverse effect of nivolumab and pembrolizumab. In this letter, we report the strong expression of PD-L1 in epithelioid granulomatous lesions in tuberculosis, sarcoidosis, Crohn's disease, and foreign body granuloma. In addition, we discussed the exacerbation of tuberculosis after anti-PD-1 antibody-based cancer immunotherapy.